Tocagen Inc. (TOCA) Reaches $9.39 After 5.00% Down Move; New Vernon Capital Holdings Ii Lifted Hdfc Bank LTD (HDB) Holding

June 14, 2018 - By Darrin Black

HDFC Bank Limited (NYSE:HDB) Logo

New Vernon Capital Holdings Ii Llc increased Hdfc Bank Ltd (HDB) stake by 10.92% reported in 2018Q1 SEC filing. New Vernon Capital Holdings Ii Llc acquired 4,912 shares as Hdfc Bank Ltd (HDB)’s stock declined 3.14%. The New Vernon Capital Holdings Ii Llc holds 49,911 shares with $4.93 million value, up from 44,999 last quarter. Hdfc Bank Ltd now has $76.68B valuation. The stock decreased 0.78% or $0.8 during the last trading session, reaching $101.5. About 381,611 shares traded. HDFC Bank Limited (NYSE:HDB) has risen 11.82% since June 14, 2017 and is uptrending. It has underperformed by 0.75% the S&P500. Some Historical HDB News: ; 03/04/2018 – HDFC EXPECTS TO REPORT INR3B PROFIT ON INVESTMENT SALE IN 4Q; 15/03/2018 – HDFC ASSET MANAGEMENT COMPANY LIMITED FILES FOR IPO; 21/04/2018 – HDFC BANK BOARD PROPOSE DIVIDEND OF INR 13/SHARE; 03/04/2018 – HDFC: AS AT DEC 31, AMOUNT IN PROVISIONS/CONTINGENCIES INR48.9B; 02/05/2018 – Franklin Templeton – India Adds Lal PathLabs, Cuts HDFC; 16/05/2018 – DELTA CORP LTD DELT.NS SAYS HDFC TRUSTEE CO LTD CUTS STAKE IN CO BY 2.08 PCT TO 4.55 PCT; 02/04/2018 – HDFC TO ANNOUNCE 4Q RESULTS ON APRIL 30; 15/03/2018 – FINAL GUIDANCE: HDFC Bank 7Y Masala Bond 8.10% (The Number); 09/04/2018 – HDFC: REVISION IN RETAIL PRIME LENDING RATE; 30/04/2018 – HDFC SAYS INR2.65B PRE-TAX GAIN ON SALE OF UNITS TO QUIKR INDIA

The stock of Tocagen Inc. (NASDAQ:TOCA) is a huge mover today! The stock decreased 3.59% or $0.35 during the last trading session, reaching $9.39. About 149,731 shares traded or 48.29% up from the average. Tocagen Inc. (NASDAQ:TOCA) has declined 44.41% since June 14, 2017 and is downtrending. It has underperformed by 56.98% the S&P500. Some Historical TOCA News: ; 20/04/2018 – Tocagen at American Academy of Neurology Meeting Apr 24; 18/04/2018 – TOCAGEN SAYS CO ELIGIBLE TO RECEIVE UP TO $127 MILLION IN UPFRONT PAYMENT; 30/04/2018 – Tocagen at PEGS Essential Protein Engineering Summit Tomorrow; 23/04/2018 – DJ Tocagen Inc, Inst Holders, 1Q 2018 (TOCA); 07/03/2018 – Tocagen Forms Golden Cross: Technicals; 18/04/2018 – TOCAGEN SAYS CO WILL BE ELIGIBLE FOR ADDITIONAL FUTURE PAYMENTS TOTALING UP TO $111 MLN UPON MEETING CERTAIN DEVELOPMENT, COMMERCIAL MILESTONES; 08/03/2018 – Tocagen 4Q Loss/Shr 55c; 16/04/2018 – Tocagen: Safety, Tolerability, Confirmation of Vector Deposition Demonstrated With Intravenous Delivery of Toca 511; 18/04/2018 – TOCAGEN INC SAYS CO ALSO ELIGIBLE TO RECEIVE DEVELOPMENT, COMMERCIAL MILESTONES, PLUS ADDITIONAL DOUBLE-DIGIT TIERED SALES ROYALTIES; 16/04/2018 – Tocagen Presents Preliminary Toca 6 Phase 1 Data in Patients with Advanced Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting 2018The move comes after 6 months negative chart setup for the $186.99M company. It was reported on Jun, 14 by We have $8.92 PT which if reached, will make NASDAQ:TOCA worth $9.35M less.

Analysts await Tocagen Inc. (NASDAQ:TOCA) to report earnings on August, 8. They expect $-0.63 earnings per share, down 12.50% or $0.07 from last year’s $-0.56 per share. After $-0.65 actual earnings per share reported by Tocagen Inc. for the previous quarter, Wall Street now forecasts -3.08% EPS growth.

More recent Tocagen Inc. (NASDAQ:TOCA) news were published by: which released: “Premarket analyst action – healthcare” on May 16, 2018. Also published the news titled: “Benzinga’s Top Upgrades, Downgrades For June 11, 2018” on June 11, 2018.‘s news article titled: “B Riley Likes Tocagen On Prospects For Company’s Brain Cancer Drug” with publication date: May 16, 2018 was also an interesting one.

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. The company has market cap of $186.99 million. The Company’s cancer-selective gene therapy platform is built on retroviral replicating vectors , which are designed to deliver therapeutic genes into the DNA of cancer cells. It currently has negative earnings. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG).

More news for HDFC Bank Limited (NYSE:HDB) were recently published by:, which released: “Stocks- Wall Street Inches Up Ahead of Fed Meeting” on June 13, 2018.‘s article titled: “New Research: Key Drivers of Growth for Klondex Mines, Sogou Inc., Nokia, HDFC Bank, Crescent Point Energy, and …” and published on June 08, 2018 is yet another important article.

Among 3 analysts covering HDFC Bank Limited (NYSE:HDB), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. HDFC Bank Limited had 5 analyst reports since August 27, 2015 according to SRatingsIntel. Zacks upgraded HDFC Bank Limited (NYSE:HDB) on Monday, September 21 to “Hold” rating. The stock has “Sell” rating by Zacks on Wednesday, September 2. As per Wednesday, September 14, the company rating was maintained by Goldman Sachs. The rating was downgraded by Zacks to “Hold” on Thursday, August 27. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, March 21.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts